Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: EtTuBrute who wrote (4334)	12/6/1999 8:53:00 PM
From: xcr600	Respond to of 19428

Ya left out some parts.. Plus the FDA still has the final word/ "...But the advisers stressed the GlucoWatch is not perfect: It sometimes gives erroneous readings, won't measure when the patient perspires too much, and is less effective at detecting life-threateningly low blood sugar than at spotting dangerous high glucose levels. Indeed patients should never decide to use insulin based on a GlucoWatch measurement without first doing a finger-stick test to doublecheck, FDA advisers and manufacturer Cygnus Inc (NasdaqNM:CYGN - news). agreed. And the FDA panel demanded that Cygnus offer a stringent education program to teach patients and doctors how to use the GlucoWatch...."